Genagon Therapeutics
Verified IntelGengagon is delivering unprecedented opportunities to fight cancer. We develop the next generation of therapeutical antibody-drug conjugates with a unique target profile and the ability to treat solid tumors, where no successful standard of care treatments is available. Our pipeline focuses on a therapeutically novel transmembrane protein class accumulating on the surface of cancer cells and tumor promoting cells within the tumor. The company is supported financially by among others, Beijer Ventures and Almi Invest.
Gengagon is delivering unprecedented opportunities to fight cancer. We develop the next generation of therapeutical antibody-drug conjugates with a unique target profile and the ability to treat solid tumors, where no successful standard of care treatments is available. Our pipeline focuses on a therapeutically novel transmembrane protein class accumulating on the surface of cancer cells and tumor promoting cells within the tumor. The company is supported financially by among others, Beijer Ventures and Almi Invest.
Corporate Firmographics
Entity classification and operating profile
- Industry
- General
- Company Type
- Privately Held
- Founded
- 2015
- Employee Bracket
- 1-10
- Estimated Revenue Range
- Undisclosed
Geographic Coordinates
Headquarters address and regional territory
- Street Address
- Nanna Svartz väg 2 Solna Stockholm
- City
- —
- Region / State
- —
- Postal Code
- 171 65
- Country
- Sweden
Digital Presence & Footprint
Verified domains, socials, and directory profiles
Frequently Asked Questions
Verified business inquiries and firmographic telemetry for Genagon Therapeutics.